Scott A. Armstrong, MD, PhD

Epigenetic Programs in MLL-rearranged leukemias

The Armstrong lab is using high throughput approaches that assess gene activity and chromosome structure in leukemias. Recent data suggest that certain mutations induce acute myelogenous leukemia (AML) by altering chromosome structure. The proteins that control the abnormal chromatin structure in these leukemias are enzymes (called histone methyltransferases) that present a tremendous opportunity for new drug development. The studies supported by Gabrielle’s Angel Foundation will assess histone methylation as a new therapeutic target in AML.